Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Mazur Leonard L	2. Issuer Name and Ticker or Trading Symbol Citius Pharmaceuticals, Inc. [ CTXR ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director __ X __ 10% Owner __ X __ Officer (give title below) _____ Other (specify below) Executive Chairman
(Last) (First) (Middle) C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR	3. Date of Earliest Transaction (MM/DD/YYYY) 4/3/2019
(Street) CRANFORD, NJ 07016 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	4/3/2019		P		1165048	A	$1.545	8020643	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Options to Purchase Common Stock ⁽¹⁾	$3.45							⁽¹⁾	9/13/2027	Common Stock	40000		40000	D
Warrant to Purchase Common Stock ⁽²⁾	$6.15							⁽²⁾	6/12/2019	Common Stock	19614		19614	D
Warrant to Purchase Common Stock ⁽²⁾	$9.9							⁽²⁾	9/30/2019	Common Stock	3171		3171	D
Warrant to Purchase Common Stock ⁽²⁾	$9.9							⁽²⁾	1/8/2020	Common Stock	4984		4984	D
Warrant to Purchase Common Stock ⁽²⁾	$7.5							⁽²⁾	8/18/2020	Common Stock	35211		35211	D
Warrant to Purchase Common Stock ⁽²⁾	$7.5							⁽²⁾	11/2/2020	Common Stock	20783		20783	D
Warrant to Purchase Common Stock ⁽²⁾	$7.5							⁽²⁾	11/20/2020	Common Stock	20664		20664	D
Warrant to Purchase Common Stock ⁽²⁾	$7.5							⁽²⁾	1/8/2021	Common Stock	13679		13679	D
Warrant to Purchase Common Stock ⁽²⁾	$7.5							⁽²⁾	3/14/2021	Common Stock	4210		4210	D
Warrant to Purchase Common Stock ⁽²⁾	$6.15							⁽²⁾	3/15/2021	Common Stock	18106		18106	D
Warrant to Purchase Common Stock	$4.125							⁽²⁾	8/8/2022	Common Stock	421400		421400	D
Warrant to Purchase Common Stock	$4.125							⁽²⁾	8/8/2022	Common Stock	11000		11000	D
Options to Purchase Common Stock ⁽³⁾	$6.75							⁽³⁾	9/12/2024	Common Stock	220000		220000	D
Warrant to Purchase Common Stock ⁽²⁾	$4.63							⁽²⁾	6/19/2023	Common Stock	106553		106553	D
Warrant to Purchase Common Stock ⁽²⁾	$2.86							⁽²⁾	9/29/2023	Common Stock	167504		167504	D
Warrant to Purchase Common Stock ⁽²⁾	$1.15							⁽²⁾	8/14/2023	Common Stock	3137255		3137255 ⁽⁴⁾	D
Options to Purchase Common Stock ⁽⁵⁾	$1.62							⁽⁵⁾	9/4/2028	Common Stock	150000		150000	D
Warrant to Purchase Common Stock ⁽²⁾	$1.42	4/3/2019		P		1165048		⁽²⁾	4/5/2021	Common Stock	1165048	⁽⁴⁾	1615048	D

Explanation of Responses:
(1)	One-third of the shares of the Company's common stock underlying the grant vest on the first anniversary of the vesting commencement date, September 13, 2018. The remaining shares of the Company's common stock underlying the grant vest in equal monthly installments at the end of each month for two years following the initial vest, provided the Reporting Person continues to serve as a member of the Company\'s Board of Directors as of each such vesting date.
(2)	The warrant is fully vested and exercisable immediately.
(3)	The option vested as to 40% of the shares of the Company's common stock on September 12, 2014 and 15% of the shares on each of September 12, 2015, March 12 and September 12, 2016 and September 12, 2017.
(4)	The purchase price of the warrants was included in the purchase price of the common stock reported in Table I.
(5)	One-third of the shares of the Company's common stock underlying the grant vest on each of the one-year, two-year and three-year anniversary of the vesting commencement date, September 4, 2018, provided that the Reporting Person provides continuous services to the Company as of each such vesting date.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Mazur Leonard L C/O CITIUS PHARMACEUTICALS, INC. 11 COMMERCE DRIVE, 1ST FLOOR CRANFORD, NJ 07016	X	X	Executive Chairman

Signatures
/s/ Alexander M. Donaldson, by power of attorney		4/5/2019
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.